Q1 2025
Ends Jan 5, 2025
Revenue
$0.3B
$0.3B to $0.3B
EPS
0.85
0.85 to 0.85
No analyst count
EPS: No analyst count
May 5, 11:06 PM UTC
stable/analyst-estimates
Healthcare
Live Price
Offline$0.95
+0.00% today
1Y Change
-36.67%
Window
Jun 27, 2025 → Jun 23, 2026
Coverage: 247 bars · Jun 27, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Global Cord Blood Corporation (CORBF) is a Healthcare stock with a market cap of $870.00M and listed on OTC. The stock last traded around $0.95 and down 36.7% across the available one-year price window (Jun 27, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +7.2%, EPS growth of -1.4%, a dividend yield of 0.0%. What stands out right now is revenue +7.2%, EPS -1.4%, free cash flow -2.6% with operating margin 49.0% and ROIC 6.3%. Valuation is more restrained than many high-expectation growth names at P/E 1.6 and price/sales 0.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CORBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
CORBF is 55.97 pts behind over the shared 1Y window.
CORBF had 79.44 pts deeper max drawdown than SPY.
CORBF beat SPY in 0 of 2 calendar years shown and trailed in 2.
CORBF
-36.67%
Normalized return
SPY
+19.30%
S&P 500
Excess Return
-55.97 pts
Relative to SPY
CORBF Max Drawdown
-88.57%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for CORBF and SPY.
| Year | CORBF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | 0.00% | +6.71% | -6.71 pts | SPY |
| 2025 | -36.67% | +11.73% | -48.39 pts | SPY |
EPS Consensus
0.85
Range 0.85 -> 0.85
No analyst count
vs prior: +4.1%Revenue Outlook
$0.3B
Range $0.3B -> $0.3B
No analyst count
vs prior: +4.1%Price Target
--
-- -> --
No analyst count
Recommendations
--
No recommendation feed
No date
Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Next Earnings
EPS --
Revenue --
No analyst count
EPS Revisions
No recent EPS revision rows
0 revision rows
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from the configured analyst feed.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.